| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 27, 2024 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/16/2024 | $3.50 | Buy | TD Cowen |
| 4/4/2024 | $3.25 | Buy | Jefferies |
| 7/12/2023 | $4.00 | Overweight | KeyBanc Capital Markets |
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company") today announced unaudited interim financial results for the third quarter ended September 30, 2024. Recent Highlights: Reported third quarter 2024 revenue of $45 million Ongoing merger cost synergy realization delivered 50% adjusted EBITDA improvement and 35% net loss improvement year-over-yearOperationalized approximately $80 million in merger synergies, expected to be fully realized in 2025, and reinforcing path to adjusted EBITDA break-even in 2026Balance sheet as of September 30, 2024, includes $368 million cash, cash equivalents, restricted cash and short-te
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market. The Company's management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on October 30, 2024, to discuss third quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webca
Delivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024 Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA for full-year 2026 Current balance sheet of $396 million cash, cash equivalents, restricted cash and short-term investments SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced unaudited interim financial results for the second quarter and six months ended June 30, 2024. "We are laser-focused on optimizing our cost structure, already seeing early integration synerg
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools' finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to th
SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the appointment of Fenel Eloi to its Board of Directors ("Board"). Eloi will also serve on the Board's Audit Committee. Eloi was most recently the Chief Financial Officer and then Chief Operating Officer of Cell Signaling Technology, Inc., where he oversaw significant growth of the business over a period of 12 years and provided leadership in the transformation of the company to a global operation. Previously, Mr. Eloi was Chief Operating Officer and Chief Financial Officer at Interleu
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
3 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)
SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)
SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)
SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)
-S-3 https://www.sec.gov/Archives/edgar/data/1162194/000110465924072927/tm2417094-1_s3.htm
The Dow Jones index closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Marygold Companies The Trade: The Marygold Companies, Inc. (NYSE:MGLD) 10% owner Nicholas & Melinda Gerber Living Trust bought a total of 80,000 shares at an average price of $1.35. To acquire these shares, it cost around $107,760. What's Happ
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that its management team will participate in the following investor conferences in the month of November: UBS Global Healthcare Conference on November 12th, 2024President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 12, 2024, at 1:15 p.m. PTJefferies London Healthcare Conference on November 19th – 21st, 2024President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 19, 2024, at 8:30 a.m. GMT Available presentations will be webcast live and available on the Investor Relat
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company") today announced unaudited interim financial results for the third quarter ended September 30, 2024. Recent Highlights: Reported third quarter 2024 revenue of $45 million Ongoing merger cost synergy realization delivered 50% adjusted EBITDA improvement and 35% net loss improvement year-over-yearOperationalized approximately $80 million in merger synergies, expected to be fully realized in 2025, and reinforcing path to adjusted EBITDA break-even in 2026Balance sheet as of September 30, 2024, includes $368 million cash, cash equivalents, restricted cash and short-te
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market. The Company's management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on October 30, 2024, to discuss third quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webca
8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)
8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)
8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)
TD Cowen initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.50
Jefferies initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.25
KeyBanc Capital Markets initiated coverage of Standard BioTools with a rating of Overweight and set a new price target of $4.00